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Introduction
Cardiomyopathies, arrhythmic syndromes, aortopathies, and other car-
diovascular diseases with Mendelian inheritance are relatively frequent
conditions for which genetic testing is recommended in various guide-
lines.1,2 The most widely recognized indication for genetic testing in
patients with these conditions is to identify a causative mutation and
subsequently provide pre-symptomatic or predictive testing of relatives
who are at risk of developing the same disease at a later stage. This
process of cascade screening of family members ensures adequate
clinical surveillance of mutation carriers and allows non-carriers to be
discharged from clinical follow-up. A number of studies have reported
a greater cost-effectiveness combining molecular screening with clinical
screening compared with isolated clinical investigations.3
Previously, genetic testing was based on conventional techniques
likeSanger sequencinganalysing genesonebyone,but recentadvances
in DNA sequencing technologies have made it possible to investigate
large numbers of disease genes simultaneously, making mutation
analysis much faster and cheaper. These new methods are known as
next-generation sequencing (NGS) and represent a major advance
in the ability to identify causative mutations in families affected by
genetic diseases (see Supplementary material online, Figure S1).4,5
However, analysis of large numbers of genes may identify a number
of sequence variants of uncertain clinical significance (VUS). As a
result, cardiologists and clinical geneticists who counsel and manage
families with inherited cardiovascular disorders are facing a major
challenge in determining the clinical relevance of NGS results.6,7
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This paper gives a brief overview of the principles of NGS, dis-
cusses the general strategies for the interpretation of sequencing
results, and reviews the implications of NGS for cardio-genetic ser-
vices. In addition, issues related to genetic counselling and ethical
considerations are discussed. A summary of viewpoints is given in
Table 1.
Methods for identification
of disease-causing mutations
Until recently, mutation analysis has been performed mostly using
Sanger sequencing in which the order of nucleotides in the coding
sequences of a gene (exons) is analysed in series one after the
other. The method is accurate and reproducible but also labour
intensive and expensive, which has limited testing to analyses of
relatively few disease genes.
NGS uses a highly parallelized sequencing process, which makes it
possible to investigate large numbers of genes simultaneously at
greater speed and at lower cost than by Sanger sequencing (see Sup-
plementary material online, Figure S1).4,5 The method is particularly
useful in the context of hereditary cardiovascular conditions, since
the number of underlying disease genes and causative mutations is
significant for most of the disorders. In addition, the size of some of
the disease genes—most notably Titin (TTN) and the Ryanodine Re-
ceptor (RyR2)—impedes the use of Sanger sequencing as an analysis
tool in clinical practice.
NGS technology can be used in different ways. Many diagnostic la-
boratories offer ‘targeted gene panels’, in which there is a focus on a
set of genes known to be associated with specific disorders. Others
provide whole exome sequencing (WES) which covers almost all
protein-coding sequences or whole-genome sequencing (WGS)
that includes nearly all non-coding sequences as well.
Targeted gene panels have been shown to generate results with
analytical quality identical to Sanger sequencing and have the advan-
tage of being faster and cheaper with a better coverage and sensitivity
than WES and WGS.4 Although WES and WGS make it possible to
perform an unbiased search for mutations in all human genes, this ap-
proach is currently considered less appropriate for routine diagnostic
purposes as not every part of the coding sequence is sufficiently
covered, which may lead to false-negative results. In addition, issues
related to management of the huge amount of data generated by
WES and WGS remain to be solved before these approaches are
suitable for routine use in a clinical setting.8,9
Interpretation of sequencing
results
With the introduction of NGS into clinical practice, the number
and size of genes investigated have increased dramatically. Since
the number of variants identified by NGS is almost proportional to
the total number of DNA bases sequenced, many more variants
are being identified and need to be classified as pathogenic, benign,
or VUS.10,11 In order to make such distinctions, a rigorous process
of interpretation is necessary to avoid misclassification and thereby
ensure correct counselling. This relies on a number of complemen-
tary investigations.
(1) Frequency of variants in healthy controls
Several public databases provide information about the fre-
quency of variants within the coding sequence of the human
genome based on WES and WGS of thousands of apparently
healthy controls. Once a sequence variant has been identified
in a patient, it is important to determine whether it is present
or absent in such databases. A high-frequency among controls
indicates that the variant identified is likely to represent normal
variation while a very low frequency or complete absence
suggests a potential disease-associated mutation.
(2) Published data
It is important to clarify whether the variant has already been
reported as disease causing. However, the evidence for caus-
ation needs careful evaluation since much of the published data
that were generated in the pre-NGS era involved a limited
number of controls. It has become evident following the intro-
duction of NGS that a significant number of rare variants previ-
ously reported to be pathogenic are in fact likely to be benign
due to their presence in the general population.12
(3) Co-segregation in families
Co-segregation of a variant with the condition in a large family
with many affected individuals usually provides strong evidence
for causation. However, families with multiple affected indivi-
duals is a rare occurrence and the most common clinical scenario
is that of a novel sequence variant in an individual with only few
or no other clinically affected relatives. Consequently, many
novel variants identified by NGS will be classified as VUS and
thereby represent an inconclusive test result at present.
(4) Likely effect on the transcribed protein and evolutionary conservation
Sequence variants exert different effects on protein structure
that may or may not be pathogenic. The probable impact on
protein function can be estimated from the type of mutation
Table 1 Summary of viewpoints on the use of
next-generation sequencing in genetic diagnosis of
hereditary cardiovascular conditions
† Before genetic testing it is important to inform the patient about the
challenges in interpretation of sequencing results of multiple genes
and discuss the implications of unsolicited findings
† In a clinical diagnostic setting only recognized disease genes should be
investigated in patients fulfilling diagnostic criteria of a specific
cardiovascular condition
† Whole exome/genome sequencing is considered to be a diagnostic
method in development andshould beused for geneticdiagnosisonly
if filtered against recognised disease genes. The coverage should
allow identification of all exomic variants in these genes
† Interpretation of sequencing results should take place in close
collaboration between bio-informaticians, cardiologists, molecular
biologists, clinical geneticists, preferably in expert centres
† Development of public databases worldwide with clinical
information and sequencing results are essential to ensure optimal
patient management
† Prospective re-evaluation of variants of uncertain significance is
essential
† Algorithms for re-contacting referring physicians and patients have to
be developed
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(nonsense, missense, splice site), the level of conservation
through evolution by comparison to DNA-sequences of other
species, and by using in silico prediction tools. These analyses
provide information about the likelihood of pathogenicity, but
cannot be used in isolation to classify a sequence variant as rele-
vant for clinical decision-making or genetic counselling.
Informed consent and ethical
considerations
The ability to sequence all of the human genome and the conse-
quent identification of many VUS presents new challenges for the
counselling of individuals before and after genetic testing. Particular
issues to consider are the possibility of reclassification of genetic
variants from benign to disease causing (or vice versa) at a later
date due to the generation of new data. In addition, unsolicited find-
ings in other genes such as recognized cancer genes are reported in
1–3% of patients undergoing WES or WGS.10 It is therefore essen-
tial to discuss with patients prior to WES or WGS whether genes
unrelated to their condition should be interpreted and whether
they would like to be informed about potentially relevant findings
in genes unrelated to the condition for which they are being
tested. Findings in such ‘actionable genes’ may potentially influence
the future health condition of the patient and their family and
thereby indicate regular follow-up to ensure timely treatment and
genetic counselling.
The ethical concerns about incidental findings and the current
technical limitations of NGS with respect to gene coverage mean
that, for thepresent,WESandWGSareconsidered tobeadiagnostic
method in development.8 We suggest that only recognized disease
genes with substantial evidence of causality should be investigated
when offering routine genetic testing. Other genes with less evidence
of causality should be classified as candidate genes and primarily
investigated for research purposes.
Sharing information in public
databases
To take the full advantage of NGS, it is important to develop dedi-
cated databases that combine sequencing data and clinical informa-
tion about patients in order to share, compare, and continuously
update knowledge for medical use. This will facilitate correct inter-
pretation of identified sequence variants, ensure clinical efficiency,
and maintain on-going evaluation of reported sequencing data.13
In contrast, if this information is not shared, there is a considerable
riskofmisinterpretation of the impact of the variants identified,which
may lead to wrongful counselling of affected families.
Complexities in diagnosis and
organisation of cardio-genetic
services
The development of NGS has not only made it feasible to offer
genetic testing in large numbers of genes and to more patients
when compared with previous methods, but it has also accelerated
the pace of new disease gene discovery. The result is an ever
growing list of candidate genes in screening protocols and greater
complexity in the interpretation of genetic variants both of which
make it necessary to develop continuing education of molecular biol-
ogists in bioinformatics and clinicians caring for patients with heredi-
tary cardiovascular conditions.
The increased availability and ever decreasing cost of NGS make it
tempting to apply less stringent indications for genetic testing.
However, it is well established that the diagnostic yield of genetic
investigations is highest in patients with familial disease who fulfil diag-
nostic criteria for the condition under investigation. In patients with
an ambiguous clinical diagnosis, it is often very difficult to establish
whether a specific sequence variant is disease causing and usually
requires careful clinical assessment of patients and their relatives.
Therefore, to ensure accurate clinical diagnosis, provide optimal
counselling and management of families with hereditary cardiovascu-
lar conditions it is essential that cardiologists, molecular biologists,
bio-informaticians, and clinical geneticists, work closely together as
a team, ideally in expert centres. This facilitates multidisciplinary
case discussion and constant review of the indications for genetic
testing, counselling strategies, and interpretation of sequencing
results. By pooling the experience of such teams in public databases
it will soon be possible to translate all the data generated by NGS into
usable knowledge for the benefit of patients and their families.
Supplementary material
Supplementary material is available at European Heart Journal online.
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